Associate Professor
Vanderbilt University Medical Center
Carlos G. Grijalva, MD MPH FIDSA. I am an Associate Professor in the Division of Pharmacoepidemiology, Department of Health Policy at Vanderbilt University Medical Center. I have appointments as faculty, scholar and/or investigator at the Vanderbilt Epidemiology Center, the Vanderbilt Center for Health Services Research, the Vanderbilt Institute for Global Health, the Vanderbilt Center for Data Science, and the Veterans Affairs Tennessee Valley Geriatric Research Education and Clinical Center (GRECC). My research interests include the study of vaccine-preventable respiratory diseases, the evaluation of medications safety and effectiveness, and methodologies for comparative effectiveness research. I am experienced in the conduct of observational studies of medications and vaccination effects, and my research is particularly focused on influenza and pneumococcal infections, and the evaluation of the effectiveness of vaccination and other preventive programs. I have led several studies quantifying the burden of influenza and other causes of acute respiratory infections, and evaluating the effects of preventative interventions on mitigating disease burden. I am currently the Co-Principal Investigator for a large household-based case ascertained study that examines the risk of influenza transmission in households in Nashville, TN. This project has been expanded to conduct a prospective case-ascertained study of SARS-CoV-2 transmission in households in TN. My current work is supported by the National Institutes of Health, the Centers for Disease Control and Prevention, the Agency for Healthcare Research and Quality, the Food and Drug Administration, among other sources. I have published more than 200 peer-reviewed articles. This year, I was elected a member of the American Society for Clinical Investigation (ASCI). I am the Co-Principal Investigator for a T32 training grant focuses on translation and implementation science within the context of a learning healthcare system, and the Principal Investigator for a NIAID K24 grant to provide training on studies of viral transmission in households.
Disclosure: AHRQ (Individual(s) Involved: Self): Grant/Research Support; Campbell Alliance (Individual(s) Involved: Self): Grant/Research Support; CDC (Individual(s) Involved: Self): Grant/Research Support; FDA (Individual(s) Involved: Self): Grant/Research Support; Merck (Individual(s) Involved: Self): Consultant; NIH (Individual(s) Involved: Self): Scientific Research Study Investigator; Pfizer (Individual(s) Involved: Self): Consultant; Sanofi (Individual(s) Involved: Self): Grant/Research Support
